Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent

International Immunopharmacology

Volumn 6, Issue 5, 2006, Pages 764-773

  Oshikawa, Tetsuya ^a   Okamoto, Masato ^a   Tano, Tomoyuki ^a   Uddin Ahmed, Sharif ^a   Sasai, Akiko ^a   Kan, Shin ^a   Moriya, Yoichiro ^b   Ryoma, Yoshiki ^b   Saito, Motoo ^b   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti tumor immunity; Cytotoxic activity; Nitric oxide; OK 432

Indexed keywords

ARGININE DERIVATIVE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; N MONOMETHYL LEVO ARGININE ACETATE; NEUTRALIZING ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNIZATION; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PICIBANIL; RNA, MESSENGER; SPLEEN; STREPTOCOCCUS PYOGENES;

EID: 33645028438     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.11.010     Document Type: Article

References (37)

1. H. Okamoto, S. Shoin, S. Koshimura, and R. Shimizu Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci Jpn J Microbiol 11 1967 323 336
2. Y. Maehara, T. Okuyama, Y. Kakeji, H. Baba, M. Furusawa, and K. Sigimachi Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion Am J Surg 168 1994 36 40
3. F. Kikkawa, M. Kawai, H. Oguchi, M. Kojima, and H. Ishikawa Randomised study of immunotherapy with OK-432 in uterine cervical carcinoma Eur J Cancer 29 1993 1542 1546
4. M. Sato, K. Harada, H. Yoshida, Y. Yura, and M. Azuma Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: association of the therapeutic effect with differentiation and apoptosis in the cancer cells Apoptosis 2 1997 227 238
5. M. Okamoto, T. Oshikawa, T. Tano, G. Ohe, and S. Furuichi Involvement of Toll-like receptor 4 signaling in interferon-γ production and antitumor effect by streptococcal agent OK-432 J Natl Cancer Inst 95 2003 316 326
6. K. Oshimi, S. Kano, F. Takaku, and K. Okumura Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432 J Natl Cancer Inst 65 1980 1265 1269
7. T. Misaki, Y. Watanabe, Y. Iida, A. Hidaka, and K. Kasagi Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy Cancer Immunol Immunother 35 1992 92 96
8. T. Fujimoto, R.B. Duda, A. Azilvasi, X. Chen, M. Mai, and M.A. O'Donnell Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state J Immunol 158 1997 5619 5626
9. S. Nakahara, T. Tsunoda, T. Baba, S. Asabe, and H. Tahara Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide Cancer Res 63 2003 4112 4118
10. T. Itoh, Y. Ueda, K. Okugawa, H. Fujiwara, and N. Fuji Streptococcal preparation OK-432 promotes functional maturation of human monocyte-derived dendritic cells Cancer Immunol Immunother 52 2003 207 214
11. H. Kuroki, T. Morisaki, K. Matsumoto, H. Onishi, and E. Baba Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use Cancer Immunol Immunother 52 2003 561 568
12. M. Okamoto, S. Furuichi, Y. Nishioka, T. Oshikawa, and T. Tano Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation Cancer Res 64 2004 5461 5470
13. S.U. Ahmed, M. Okamoto, T. Oshikawa, T. Tano, and A. Sasai Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4 J Immunother 27 2004 432 441
14. M. Okamoto, R. Kaji, H. Kasetani, H. Yoshida, and Y. Moriya Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432 J Immunother 13 1993 232 242
15. M. Okamoto, H. Gohda, G. Ohe, H. Yoshida, and T. Matsuno Cytokine-inducing activity and anti-tumor effect of liposome-incorporated interferon-γ-inducing molecule derived from OK-432, a streptococcal preparation J Immunother 23 2000 94 103
16. M. Okamoto, G. Ohe, T. Oshikawa, S. Furuichi, and H. Nishikawa Enhancement of anti-cancer immunity by a lipoteichoic-acid-related molecule isolated from a penicillin-killed group A Streptococcus Cancer Immunol Immunother 50 2001 408 416
17. M. Okamoto, T. Oshikawa, G. Ohe, S. Furuichi, and H. Nishikawa Comparison of cytokine-inducing activity in a lipoteichoic acid-related molecule isolated from a penicillin-killed group A Streptococcus and untreated bacteria Int Immunopharmacol 1 2001 1957 1968
18. K. Ryoyama Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide Cancer Immunol Immunother 35 1992 7 13
19. Y. Huang, Y. Xu, H. Yamagishi, and A. Hagiwara Tumor cytotoxicity of peritoneal macrophages induced by OK-432 Anticancer Drugs 12 2001 781 785
20. K. Asai., H. Kato, K. Hirose, K. Akaogi, and S. Kimura PSK- and OK-432-induced immunomodulation of inducible nitric oxide (NO) synthase gene expression in mouse peritoneal polymorphonuclear leukocytes and NO-mediated cytotoxicity Immunopharmacol Immunotoxicol 22 2000 221 235
21. K. Xie, S. Huang, Z. Dong, S.H. Juang, Y. Wang, and I.J. Fidler Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene J Natl Cancer Inst 89 1997 421 427
22. K. Xie, S. Huang, Z. Dong, S.H. Juang, and M. Gutman Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells J Exp Med 181 1995 1333 1343
23. L. Limin, R.G. Kilbourn, J. Adams, and I.J. Fidler Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells Cancer Res 51 1991 2531 2535
24. U.K. Meßmer, J.C. Reed, and B. Brune Bcl-2 protects macrophages from nitric oxide-induced apoptosis J Biol Chem 271 1996 20192 20197
25. M.A. Schwarz, J.S. Lazo, J.C. Yalowich, W.P. Allen, and M. Whitmore Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide Proc Natl Acad Sci U S A 92 1995 4452 4456
26. M. Okamoto, G. Ohe, S. Furuichi, H. Nishikawa, and T. Oshikawa Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: Role of natural killer cells Anticancer Res 22 2002 3229 3240
27. E.W. Lamon, R.A. Gatti, R. Kiessling, and E.M. Fenyo Comparison of the allospecific and viral-specific immune responses to irradiated versus formaldehyde-fixed allogeneic Molony lymphoma cells in CBA mice Cancer Res 35 1975 962 969
28. A.A. Alfieri, and E.W. Hahn An in situ method for estimating cell survival in a solid tumor Cancer Res 38 1978 3006 3011
29. M.R. Ruff, and G.E. Gifford Tumor necrosis factor E. Pick Lymphokines 1981 Academic Press New York 380 385
30. T. Timonen, and E. Saksela A simplified isotope release assay for cell-mediated cytotoxicity against anchorage-dependent target cells J Immunol Methods 18 1977 123 132
31. P. Chomczynski, and N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction Anal Biochem 162 1987 156 159
32. N. Miyasaka, and Y. Hirata Nitric oxide and inflammatory arthritides Life Sci 61 1997 2073 2081
33. D.M. Vans, and S.H. Ralston Nitric oxide and bone J Bone Miner Res 11 1996 300 305
34. Oshikawa T., Okamoto M., Tano T., Sasai A., Kan S., et al. J Immunother 2005; in press.
35. S. Di Marco, R. Mazroui, P. Dallaire, S. Chittur, and S.A. Tenenbaum NF-κB-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release Mol Cell Biol 25 2005 6533 6545
36. M. Figueras, S. Busquets, N. Carbo, E. Barreiro, and V. Almendro Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats FEBS Lett 569 2004 201 206
37. V. Badovinac, V. Trajkovic, and M. Mostarica-Stojkovic Nitric oxide promotes growth and major histocompatibility complex-unrestricted cytotoxicity of interleukin-2-activated rat lymphocytes Scand J Immunol 52 2000 62 70